Takeda and Arbor sign licensing agreement for blood pressure drugs in US

15th September 2013 (Last Updated September 15th, 2013 18:30)

Japan-based Takeda Pharmaceutical Company has entered into a license, development and commercialisation agreement with Arbor Pharmaceuticals Ireland for Edarbi (azilsartan medoxomil) and Edarbyclor (azilsartan medoxomil and chlorthalidone) in the US.

Japan-based Takeda Pharmaceutical Company has entered into a license, development and commercialisation agreement with Arbor Pharmaceuticals Ireland for Edarbi (azilsartan medoxomil) and Edarbyclor (azilsartan medoxomil and chlorthalidone) in the US.

Pursuant to the terms of the deal, Arbor will have exclusive rights to market and sell Edarbi and Edarbyclor in the US market effective immediately.

Under the deal, Takeda will secure an upfront payment along with a series of future milestone and royalty payments based upon sales of the Edarbi family of products.

Takeda Pharmaceuticals USA president Douglas Cole said the company maintains its global commitment to find new therapies and expand upon the cardiovascular metabolic franchise.

"This is an opportunity to capture the value that we've created in developing and launching the EDARBI family of products while positioning us to optimise our commercial resources to support our recent and anticipated launches of new products," Cole said.

"This is an opportunity to capture the value that we've created in developing and launching the EDARBI family of products while positioning us to optimise our commercial resources to support our recent and anticipated launches of new products."

"We are pleased to entrust the EDARBI family in the United States to Arbor who will continue to ensure EDARBI products are available as a treatment option to patients with hypertension."

Edarbi, an angiotensin II receptor blocker (ARB), lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone, which naturally exists within the body.

It was developed by Takeda for the treatment of hypertension to lower blood pressure in adults, either alone or in combination with other antihypertensive agents.

The recommended dose of Edarbi in adults is 80mg taken once daily and the drug is currently approved in the Canada, Europe, Mexico and US.

Edarbyclor, a fixed-dose combination therapy, is indicated for the treatment of hypertension to lower blood pressure in adults.

The drug combines azilsartan medoxomil and chlorthalidone in a single tablet; it has a recommended starting dose of 40/12.5mg taken orally once daily in adults.

Arbor president and CEO Ed Schutter said: "We are excited about our acquisition of US rights to EDARBI and EDARBYCLOR and look forward to representing these important brands to patients and healthcare providers."

Hypertension (high blood pressure) is a chronic medical state in which blood pressure is raised to levels of 140mm Hg or greater systolic and/or 90mm Hg or greater diastolic.

Around 67 million people are affected by hypertension in the US while nearly one billion people are affected worldwide, which is expected to rise to 1.5 billion by 2025.